secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K/A
Filed at:   2026-08-13T20:05:24+00:00
Accession:  0001104659-26-095892
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio CEO Koblish separation agreement: 12-month salary, equity acceleration
-------------------------------------------------------------------------------

- Separation Agreement executed Aug 7, 2026; CEO departure effective Aug 3, 2026.
- Severance: 12 months base salary paid ratably over 12 months; COBRA premiums paid for 12 months.
- All equity awards accelerate and fully vest; option exercise period extended to Dec 31, 2027.
- Performance stock units remain eligible to vest on 2026 revenue/gross margin goals; vest at target on change in control.
- Includes general release and waiver of claims against TELA Bio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465926095892/0001104659-26-095892-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465926095892/tm2622979d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-095892

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer